王碧辉, 朱玥洁, 张玉莲, 陈立乔, 丁剑冰, 陈志芳. 新型免疫检查点SIGLEC9在宫颈癌中的表达及临床相关性分析[J]. 中国肿瘤临床, 2024, 51(4): 178-185. DOI: 10.12354/j.issn.1000-8179.2024.20240182
引用本文: 王碧辉, 朱玥洁, 张玉莲, 陈立乔, 丁剑冰, 陈志芳. 新型免疫检查点SIGLEC9在宫颈癌中的表达及临床相关性分析[J]. 中国肿瘤临床, 2024, 51(4): 178-185. DOI: 10.12354/j.issn.1000-8179.2024.20240182
shu
Bihui Wang, Yuejie Zhu, Yulian Zhang, Liqiao Chen, Jianbing Ding, Zhifang Chen. Expression and clinical correlation analysis of the novel immune checkpoint SIGLEC9 in cervical cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 51(4): 178-185. DOI: 10.12354/j.issn.1000-8179.2024.20240182
Citation: Bihui Wang, Yuejie Zhu, Yulian Zhang, Liqiao Chen, Jianbing Ding, Zhifang Chen. Expression and clinical correlation analysis of the novel immune checkpoint SIGLEC9 in cervical cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 51(4): 178-185. DOI: 10.12354/j.issn.1000-8179.2024.20240182
shu

新型免疫检查点SIGLEC9在宫颈癌中的表达及临床相关性分析

Expression and clinical correlation analysis of the novel immune checkpoint SIGLEC9 in cervical cancer

    摘要
  • 摘要:
    目的 探讨新型免疫检查点SIGLEC9及SIGLEC9+ T细胞在宫颈癌中的表达情况及SIGLEC9与临床相关性分析。
    方法 前瞻性收集2022年5月至2023年10月，于新疆医科大学第一附属医院行手术治疗或病理活检的宫颈癌患者的宫颈组织石蜡标本132例作为宫颈癌组，选取同期收治的良性子宫肌瘤行子宫全切患者的正常宫颈组织石蜡标本58例作为正常对照组；同时收集行手术治疗或病理活检的宫颈癌患者的外周血108例为宫颈癌组，选取同期健康人群的外周血86例为正常对照组。使用生物信息学技术和免疫组织化学染色、流式细胞术及双重免疫荧光染色检测SIGLEC9及SIGLEC9+ T细胞在宫颈癌中的表达情况，并与临床指标进行相关性分析。
    结果 免疫组织化学染色及双重免疫荧光染色结果显示SIGLEC9及SIGLEC9+ T细胞在宫颈癌组织中高表达（P<0.05）；流式细胞术结果显示SIGLEC9+ CD4+ T和SIGLEC9+ CD8+ T细胞在宫颈癌外周血中表达增高（P<0.05）。SIGLEC9高表达与肿瘤直径、FIGO分期、淋巴结转移、HPV感染情况相关（P<0.05）。
    结论 新型免疫检查点SIGLEC9在宫颈癌组织中高表达，且在宫颈癌组织中SIGLEC9+ T细胞浸润较多。SIGLEC9为宫颈癌的免疫逃逸机制提供新的研究方向，并为宫颈癌的免疫治疗提供新的治疗靶点。

     

    Abstract:
    Objective To investigate the expression of the novel immune checkpoint SIGLEC9 and SIGLEC9+ T cells in cervical cancer and its clinical correlation.
    Methods A total of 132 paraffin-embedded specimens of cervical tissue from patients with cervical cancer who underwent surgical treatment or pathological biopsy at The First Affiliated Hospital of Xinjiang Medical University from May 2022 to October 2023 were included for study. In addition, 58 paraffin-embedded specimens of normal cervical tissue from patients with benign uterine leiomyomas who underwent total uterine excision during the same period were selected as normal controls. Furthermore, 108 peripheral blood samples from patients with cervical cancer who underwent surgical treatment or pathological biopsy were collected for study, and 86 peripheral blood samples from healthy individuals during the same time period were selected as controls. Bioinformatics technology, immunohistochemical (IHC) staining, flow cytometry, and double immunofluorescence (IF) staining were used to assess the expression of SIGLEC9 and SIGLEC9+ T cells in cervical cancer, followed by correlation analysis with clinical indicators.
    Results The bioinformatics, IHC, and double IF staining results showed that SIGLEC9 and SIGLEC9+ T cells were highly expressed in cervical cancer tissues (P<0.05). The flow cytometry results showed that SIGLEC9+ CD4+ T and SIGLEC9+ CD8+ T cells were increased in the peripheral blood of patients with cervical cancer (P<0.05). SIGLEC9 expression correlated with tumor size, FIGO stage, lymph node metastasis, and human papillomavirus (HPV) infection (P<0.05).
    Conclusions The novel immune checkpoint SIGLEC9 was highly expressed in cervical cancer tissues, and SIGLEC9+ T cells infiltrated cervical cancer tissues. In vitro cell experiments showed that SIGLEC9 affects T cell function. In summary, SIGLEC9 provides a novel research direction for understanding the immune escape mechanism of cervical cancer and a novel therapeutic target for cervical cancer immunotherapy.

     

    • HTML全文
    • 参考文献(18)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回